These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 28554411)

  • 61. The association between biomarkers in cerebrospinal fluid and structural changes in the brain in patients with Alzheimer's disease.
    Li X; Li TQ; Andreasen N; Wiberg MK; Westman E; Wahlund LO
    J Intern Med; 2014 Apr; 275(4):418-27. PubMed ID: 24237038
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Cerebrospinal Fluid Biomarkers for Target Engagement and Efficacy in Clinical Trials for Alzheimer's and Parkinson's Diseases.
    Parnetti L; Eusebi P; Lleó A
    Front Neurol Neurosci; 2016; 39():117-23. PubMed ID: 27463974
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Sleep disturbances, cognitive decline, and AD biomarkers alterations in early Parkinson's disease.
    Zhong R; Gan C; Sun H; Zhang K
    Ann Clin Transl Neurol; 2024 Jul; 11(7):1831-1839. PubMed ID: 38764318
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Discovery, validation and optimization of cerebrospinal fluid biomarkers for use in Parkinson's disease.
    Farotti L; Paciotti S; Tasegian A; Eusebi P; Parnetti L
    Expert Rev Mol Diagn; 2017 Aug; 17(8):771-780. PubMed ID: 28604235
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Oligomeric α-synuclein and β-amyloid variants as potential biomarkers for Parkinson's and Alzheimer's diseases.
    Williams SM; Schulz P; Sierks MR
    Eur J Neurosci; 2016 Jan; 43(1):3-16. PubMed ID: 26332448
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Tau protein, beta-amyloid₁₋₄₂ and clusterin CSF levels in the differential diagnosis of Parkinsonian syndrome with dementia.
    Vranová HP; Hényková E; Kaiserová M; Menšíková K; Vaštík M; Mareš J; Hluštík P; Zapletalová J; Strnad M; Stejskal D; Kaňovský P
    J Neurol Sci; 2014 Aug; 343(1-2):120-4. PubMed ID: 24928081
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Decoupling of Global Brain Activity and Cerebrospinal Fluid Flow in Parkinson's Disease Cognitive Decline.
    Han F; Brown GL; Zhu Y; Belkin-Rosen AE; Lewis MM; Du G; Gu Y; Eslinger PJ; Mailman RB; Huang X; Liu X
    Mov Disord; 2021 Sep; 36(9):2066-2076. PubMed ID: 33998068
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Cross-sectional and longitudinal associations of motor fluctuations and non-motor predominance with cerebrospinal τ and Aβ as well as dementia-risk in Parkinson's disease.
    Modreanu R; Cerquera SC; Martí MJ; Ríos J; Sánchez-Gómez A; Cámara A; Fernández M; Compta Y
    J Neurol Sci; 2017 Feb; 373():223-229. PubMed ID: 28131192
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Cerebrospinal fluid biomarkers for neuropsychological symptoms in early stage of late-onset Alzheimer's disease.
    Kuo HC; Yen HC; Huang CC; Hsu WC; Wei HJ; Lin CL
    Int J Neurosci; 2015; 125(10):747-54. PubMed ID: 25290083
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Association of elevated cerebrospinal fluid levels of the longevity protein α-Klotho with a delayed onset of cognitive impairment in Parkinson's disease patients.
    Zimmermann M; Fandrich M; Jakobi M; Röben B; Wurster I; Lerche S; Schulte C; Zimmermann S; Deuschle C; Schneiderhan-Marra N; Gasser T; Brockmann K
    Eur J Neurol; 2024 Oct; 31(10):e16388. PubMed ID: 38946703
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Performance of aβ1-40, aβ1-42, total tau, and phosphorylated tau as predictors of dementia in a cohort of patients with mild cognitive impairment.
    Parnetti L; Chiasserini D; Eusebi P; Giannandrea D; Bellomo G; De Carlo C; Padiglioni C; Mastrocola S; Lisetti V; Calabresi P
    J Alzheimers Dis; 2012; 29(1):229-38. PubMed ID: 22232006
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Clinical criteria for subtyping Parkinson's disease: biomarkers and longitudinal progression.
    Fereshtehnejad SM; Zeighami Y; Dagher A; Postuma RB
    Brain; 2017 Jul; 140(7):1959-1976. PubMed ID: 28549077
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Cortical Thinning Associated with Age and CSF Biomarkers in Early Parkinson's Disease Is Modified by the SNCA rs356181 Polymorphism.
    Sampedro F; Marín-Lahoz J; Martínez-Horta S; Pagonabarraga J; Kulisevsky J
    Neurodegener Dis; 2018; 18(5-6):233-238. PubMed ID: 30336481
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Mild cognitive impairment: an update in Parkinson's disease and lessons learned from Alzheimer's disease.
    Goldman JG; Aggarwal NT; Schroeder CD
    Neurodegener Dis Manag; 2015 Oct; 5(5):425-43. PubMed ID: 26517759
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Cognitive decline in Parkinson disease.
    Aarsland D; Creese B; Politis M; Chaudhuri KR; Ffytche DH; Weintraub D; Ballard C
    Nat Rev Neurol; 2017 Apr; 13(4):217-231. PubMed ID: 28257128
    [TBL] [Abstract][Full Text] [Related]  

  • 76. A task-specific cognitive domain decline is correlated with plasma and neuroimaging markers in patients with Parkinson's disease.
    Li CH; Chen TF; Peng PL; Lin CH
    J Neurol; 2022 Dec; 269(12):6530-6543. PubMed ID: 35965282
    [TBL] [Abstract][Full Text] [Related]  

  • 77. The associations of cerebrospinal fluid biomarkers with cognition, and rapid eye movement sleep behavior disorder in early Parkinson's disease.
    Tao M; Dou K; Xie Y; Hou B; Xie A
    Front Neurosci; 2022; 16():1049118. PubMed ID: 36507360
    [TBL] [Abstract][Full Text] [Related]  

  • 78. APOE, thought disorder, and SPARE-AD predict cognitive decline in established Parkinson's disease.
    Tropea TF; Xie SX; Rick J; Chahine LM; Dahodwala N; Doshi J; Davatzikos C; Shaw LM; Van Deerlin V; Trojanowski JQ; Weintraub D; Chen-Plotkin AS
    Mov Disord; 2018 Feb; 33(2):289-297. PubMed ID: 29168904
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Alpha-Synuclein as a Biomarker for Parkinson's Disease.
    Atik A; Stewart T; Zhang J
    Brain Pathol; 2016 May; 26(3):410-8. PubMed ID: 26940058
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Plasma total tau predicts executive dysfunction in Parkinson's disease.
    Lin WT; Shaw JS; Cheng FY; Chen PH
    Acta Neurol Scand; 2022 Jan; 145(1):30-37. PubMed ID: 34398474
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.